BioKangtai's Adenovirus Vector COVID-19 Vaccine Obtained EUA in Indonesia

11/03 .2021

BioKangtai's Adenovirus Vector COVID-19 Vaccine Obtained EUA in Indonesia

BioKangtai's Adenovirus Vector COVID-19 Vaccine Obtained EUA in Indonesia
China's BioKangtai Begins First Shipment of AstraZeneca's COVID-19 Shot

11/18 .2021

China's BioKangtai Begins First Shipment of AstraZeneca's COVID-19 Shot

China's BioKangtai Begins First Shipment of AstraZeneca's COVID-19 Shot
Kangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported for the First Time

11/19 .2021

Kangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported for the First Time

Kangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported for the First Time
BioKangtai 30 Million Doses of Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported

12/30 .2021

BioKangtai 30 Million Doses of Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported

BioKangtai 30 Million Doses of Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Exported
BioKangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Was Approved As Booster Dose in Indonesia

01/11 .2022

BioKangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Was Approved As Booster Dose in Indonesia

BioKangtai Adenovirus Vector COVID-19 Vaccine (KCONECAVAC) Was Approved As Booster Dose in Indonesia
Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.

09/12 .2024

Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.

Marks the First Entry of Biokangtai's 13-valent Pneumococcal Vaccine into Southeast Asian Market
< 123 >